Business Context and Reporting Period
Company: Cytokinetics, Incorporated (CYTK)
Filing Type: Form 8-K (Current Report)
Date of Report: August 13, 2026
Principal Executive Offices: South San Francisco, California
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a legal event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the initiation of litigation. On August 13, 2026, Cytokinetics filed a complaint in the United States District Court for the District of Delaware against Bristol-Myers Squibb Company and MyoKardia, Inc.
Guidance, Outlook, and Legal Contingencies
Legal Action Details
- Subject: Declaratory judgment action regarding U.S. Patent No. 12,616,697 (the "'697 patent").
- Claims: The Company seeks a judgment that it does not infringe the patent and that the patent claims are invalid.
- Product Involved: MYQORZO (aficamten).
- Requested Relief:
- Declaration of non-infringement and invalidity.
- Preliminary and permanent injunction against defendants threatening or initiating infringement litigation against the Company or its customers/distributors.
- Award of costs and reasonable attorneys' fees under 35 U.S.C. § 285.
- Jury trial on all triable issues.
Management Commentary and Risks
Management intends to vigorously assert its legal rights. However, the Company explicitly states that the outcome of any litigation is inherently uncertain. The Company will provide updates in future SEC filings as required or appropriate and does not intend to comment further on the matter at this time.
Investor Verification Checklist
- Verify the status of U.S. Patent No. 12,616,697 and its relevance to MYQORZO (aficamten).
- Monitor future filings for updates on the litigation timeline and any responses from Bristol-Myers Squibb or MyoKardia.
- Assess the potential financial impact of legal fees and the risk of an injunction on MYQORZO sales.
- Review the Company's most recent 10-K or 10-Q for baseline financial data, as this 8-K contains no financial metrics.